5 Best Medical Stocks Under $5

1. Karyopharm Therapeutics Inc. (NASDAQ:KPTI)

Number of Hedge Fund Holders: 21

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) targets nuclear export with its cancer drugs. They battle diseases such as myeloma and lymphomas by inhibiting nuclear export compounds such as the XPO1 protein. The company is headquartered in Newton, Massachusetts.

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) second quarter saw the firm grow its revenue by 76% annually as it reported $39.7 million in the segment. The bulk of this revenue was contributed by the $29 million worth of sales in the United States, which marked 44% annual growth. Additionally, the firm’s compounded annual revenue growth rates stand at 332%, 192%, and 146% for the past five, three, and one year, respectively.

Karyopharm Therapeutics Inc. (NASDAQ:KPTI)’s XPOVIO treatment for myeloma penetrated 67% of the top 20% of patients in the U.S. in the second quarter, a significant achievement as 80% of the total patients come from the top 20%. Baird lowered the firm’s share price target to $14 (its current share price is $4.55) from $17 in August 2022 as it shared that the revenue guidance for XPOVIO had been lowered.

Insider Monkey surveyed 895 hedge fund portfolios for their June quarter of 2022 holdings to discover that 21 had invested in the firm.

Out of these, Karyopharm Therapeutics Inc. (NASDAQ:KPTI)’s largest investor is William Leland Edwards’s Palo Alto Investors which owns 5.6 million shares that are worth $25 million.

Disclosure: None. You can also take a look at Cheap Dividend Stocks To Invest In and 10 Best Stocks to Buy According to Billionaire Dan Loeb.

Follow Insider Monkey on Twitter